SCHEMBL2878387

SCHEMBL2878387

COc1ccccc1C(=O)NC(c1ccccc1)C1CCC(NS(=O)(=O)N2CCC(c3ccccc3)CC2)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 1/20 0.46
ALDH1A1 P00352 5/20 0.45
HPGD P15428 1/20 0.45
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPK1 P28482 1/20 0.43
MMP2 P08253 1/20 0.42
MMP13 P45452 1/20 0.42
POLB P06746 1/20 0.41
CCR5 P51681 1/20 0.41
USP30 Q70CQ3 1/20 0.40
MRGPRX1 Q96LB2 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857658 0.91 KMT2A (0.55) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2854756 0.88 KCNA5 (0.49) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2857096 0.88 HPGD (0.48) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2861504 0.87 ALDH1A1 (0.47) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2867485 0.86 KCNA5 (0.47) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2867561 0.84 MAPT (0.52) KCNA5ALDH1A1HPGDKMT2AMAPK1
SCHEMBL2853429 0.84 MAPT (0.44) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2858832 0.84 KCNA5 (0.45) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL5348976 0.82 KCNA5 (0.42) KCNA5ALDH1A1HPGDMEN1KMT2A
SCHEMBL2860891 0.81 KCNA5 (0.44) KCNA5ALDH1A1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 KCNA5 23/4885ALDH1A1 4075/4885HPGD 3115/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 KCNA5 23/4885ALDH1A1 4075/4885HPGD 3115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.